NCT06054191View on ClinicalTrials.gov

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2027

Conditions
NSCLCBRAF V600 MutationMET Exon 14 Mutation
Interventions
DRUG

Dabrafenib + Trametinib

Dabrafenib 150mg BID + Trametinib 2mg QD/（2 cycles）

DRUG

Capmatinib

Capmatinib 400mg BID/（2 cycles）

Trial Locations (1)

Unknown

Cancer Center of Sun-Yat Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER